Hepatitis B Vaccine Market Size - Global Industry, Share, Analysis, Trends and Forecast 2023 - 2032
CHAPTER 1. Industry Overview of Hepatitis B Vaccine Market
1.1. Definition and Scope
1.1.1. Definition of Hepatitis B Vaccine
1.1.2. Market Segmentation
1.1.3. Years Considered for the Study
1.1.4. Assumptions and Acronyms Used
1.1.4.1. Market Assumptions and Market Forecast
1.1.4.2. Acronyms Used in Global Hepatitis B Vaccine Market
1.2. Summary
1.2.1. Executive Summary
1.2.2. Hepatitis B Vaccine Market By Type
1.2.3. Hepatitis B Vaccine Market By Dose
1.2.4. Hepatitis B Vaccine Market By End-User
1.2.5. Hepatitis B Vaccine Market By Region
CHAPTER 2. Research Approach
2.1. Methodology
2.1.1. Research Programs
2.1.2. Market Size Estimation
2.1.3. Market Breakdown and Data Triangulation
2.2. Data Source
2.2.1. Secondary Sources
2.2.2. Primary Sources
CHAPTER 3. Market Dynamics And Competition Analysis
3.1. Market Drivers
3.1.1. Driver 1
3.1.2. Driver 2
3.2. Restraints and Challenges
3.2.1. Restraint 1
3.2.2. Restraint 2
3.3. Growth Opportunities
3.3.1. Opportunity 1
3.3.2. Opportunity 2
3.4. Porter’s Five Forces Analysis
3.4.1. Bargaining Power of Suppliers
3.4.2. Bargaining Power of Buyers
3.4.3. Threat of Substitute
3.4.4. Threat of New Entrants
3.4.5. Degree of Competition
3.5. Market Concentration Ratio and Market Maturity Analysis of Hepatitis B Vaccine Market
3.5.1. Go To Market Strategy
3.5.1.1. Introduction
3.5.1.2. Growth
3.5.1.3. Maturity
3.5.1.4. Saturation
3.5.1.5. Possible Development
3.6. Technological Roadmap for Hepatitis B Vaccine Market
3.7. Value Chain Analysis
3.7.1. List of Key Manufacturers
3.7.2. List of Customers
3.7.3. Level of Integration
3.8. Cost Structure Analysis
3.8.1. Price Trend of Key Raw Materials
3.8.2. Raw Material Suppliers
3.8.3. Proportion of Manufacturing Cost Structure
3.8.3.1. Raw Material
3.8.3.2. Labor Cost
3.8.3.3. Manufacturing Expense
3.9. Regulatory Compliance
3.10. Competitive Landscape, 2022
3.10.1. Player Positioning Analysis
3.10.2. Key Strategies Adopted By Leading Players
CHAPTER 4. Manufacturing Plant Analysis
4.1. Manufacturing Plant Location and Establish Date of Major Manufacturers in 2022
4.2. R&D Status of Major Manufacturers in 2022
CHAPTER 5. Hepatitis B Vaccine Market By Type
5.1. Introduction
5.2. Hepatitis B Vaccine Revenue By Type
5.2.1. Hepatitis B Vaccine Revenue (USD Billion) and Forecast, By Type, 2020-2032
5.2.2. Single Antigen Hepatitis B Vaccine
5.2.2.1. Single Antigen Hepatitis B Vaccine Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
5.2.3. Combination Vaccines
5.2.3.1. Combination Vaccines Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
CHAPTER 6. Hepatitis B Vaccine Market By Dose
6.1. Introduction
6.2. Hepatitis B Vaccine Revenue By Dose
6.2.1. Hepatitis B Vaccine Revenue (USD Billion) and Forecast, By Dose, 2020-2032
6.2.2. 3-Dose Schedule
6.2.2.1. 3-Dose Schedule Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
6.2.3. 2-Dose Schedule
6.2.3.1. 2-Dose Schedule Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
6.2.4. Alternate Schedule
6.2.4.1. Alternate Schedule Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
CHAPTER 7. Hepatitis B Vaccine Market By End-User
7.1. Introduction
7.2. Hepatitis B Vaccine Revenue By End-User
7.2.1. Hepatitis B Vaccine Revenue (USD Billion) and Forecast, By End-User, 2020-2032
7.2.2. Hospitals
7.2.2.1. Hospitals Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
7.2.3. Clinics
7.2.3.1. Clinics Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
7.2.4. Others
7.2.4.1. Others Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
CHAPTER 8. North America Hepatitis B Vaccine Market By Country
8.1. North America Hepatitis B Vaccine Market Overview
8.2. U.S.
8.2.1. U.S. Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Type, 2020-2032
8.2.2. U.S. Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Dose, 2020-2032
8.2.3. U.S. Hepatitis B Vaccine Revenue (USD Billion) and Forecast By End-User, 2020-2032
8.3. Canada
8.3.1. Canada Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Type, 2020-2032
8.3.2. Canada Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Dose, 2020-2032
8.3.3. Canada Hepatitis B Vaccine Revenue (USD Billion) and Forecast By End-User, 2020-2032
8.4. North America PEST Analysis
CHAPTER 9. Europe Hepatitis B Vaccine Market By Country
9.1. Europe Hepatitis B Vaccine Market Overview
9.2. U.K.
9.2.1. U.K. Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Type, 2020-2032
9.2.2. U.K. Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Dose, 2020-2032
9.2.3. U.K. Hepatitis B Vaccine Revenue (USD Billion) and Forecast By End-User, 2020-2032
9.3. Germany
9.3.1. Germany Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Type, 2020-2032
9.3.2. Germany Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Dose, 2020-2032
9.3.3. Germany Hepatitis B Vaccine Revenue (USD Billion) and Forecast By End-User, 2020-2032
9.4. France
9.4.1. France Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Type, 2020-2032
9.4.2. France Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Dose, 2020-2032
9.4.3. France Hepatitis B Vaccine Revenue (USD Billion) and Forecast By End-User, 2020-2032
9.5. Spain
9.5.1. Spain Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Type, 2020-2032
9.5.2. Spain Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Dose, 2020-2032
9.5.3. Spain Hepatitis B Vaccine Revenue (USD Billion) and Forecast By End-User, 2020-2032
9.6. Rest of Europe
9.6.1. Rest of Europe Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Type, 2020-2032
9.6.2. Rest of Europe Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Dose, 2020-2032
9.6.3. Rest of Europe Hepatitis B Vaccine Revenue (USD Billion) and Forecast By End-User, 2020-2032
9.7. Europe PEST Analysis
CHAPTER 10. Asia Pacific Hepatitis B Vaccine Market By Country
10.1. Asia Pacific Hepatitis B Vaccine Market Overview
10.2. China
10.2.1. China Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Type, 2020-2032
10.2.2. China Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Dose, 2020-2032
10.2.3. China Hepatitis B Vaccine Revenue (USD Billion) and Forecast By End-User, 2020-2032
10.3. Japan
10.3.1. Japan Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Type, 2020-2032
10.3.2. Japan Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Dose, 2020-2032
10.3.3. Japan Hepatitis B Vaccine Revenue (USD Billion) and Forecast By End-User, 2020-2032
10.4. India
10.4.1. India Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Type, 2020-2032
10.4.2. India Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Dose, 2020-2032
10.4.3. India Hepatitis B Vaccine Revenue (USD Billion) and Forecast By End-User, 2020-2032
10.5. Australia
10.5.1. Australia Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Type, 2020-2032
10.5.2. Australia Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Dose, 2020-2032
10.5.3. Australia Hepatitis B Vaccine Revenue (USD Billion) and Forecast By End-User, 2020-2032
10.6. South Korea
10.6.1. South Korea Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Type, 2020-2032
10.6.2. South Korea Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Dose, 2020-2032
10.6.3. South Korea Hepatitis B Vaccine Revenue (USD Billion) and Forecast By End-User, 2020-2032
10.7. Rest of Asia-Pacific
10.7.1. Rest of Asia-Pacific Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Type, 2020-2032
10.7.2. Rest of Asia-Pacific Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Dose, 2020-2032
10.7.3. Rest of Asia-Pacific Hepatitis B Vaccine Revenue (USD Billion) and Forecast By End-User, 2020-2032
10.8. Asia Pacific PEST Analysis
CHAPTER 11. Latin America Hepatitis B Vaccine Market By Country
11.1. Latin America Hepatitis B Vaccine Market Overview
11.2. Brazil
11.2.1. Brazil Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Type, 2020-2032
11.2.2. Brazil Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Dose, 2020-2032
11.2.3. Brazil Hepatitis B Vaccine Revenue (USD Billion) and Forecast By End-User, 2020-2032
11.3. Mexico
11.3.1. Mexico Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Type, 2020-2032
11.3.2. Mexico Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Dose, 2020-2032
11.3.3. Mexico Hepatitis B Vaccine Revenue (USD Billion) and Forecast By End-User, 2020-2032
11.4. Rest of Latin America
11.4.1. Rest of Latin America Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Type, 2020-2032
11.4.2. Rest of Latin America Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Dose, 2020-2032
11.4.3. Rest of Latin America Hepatitis B Vaccine Revenue (USD Billion) and Forecast By End-User, 2020-2032
11.5. Latin America PEST Analysis
CHAPTER 12. Middle East & Africa Hepatitis B Vaccine Market By Country
12.1. Middle East & Africa Hepatitis B Vaccine Market Overview
12.2. GCC
12.2.1. GCC Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Type, 2020-2032
12.2.2. GCC Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Dose, 2020-2032
12.2.3. GCC Hepatitis B Vaccine Revenue (USD Billion) and Forecast By End-User, 2020-2032
12.3. South Africa
12.3.1. South Africa Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Type, 2020-2032
12.3.2. South Africa Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Dose, 2020-2032
12.3.3. South Africa Hepatitis B Vaccine Revenue (USD Billion) and Forecast By End-User, 2020-2032
12.4. Rest of Middle East & Africa
12.4.1. Rest of Middle East & Africa Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Type, 2020-2032
12.4.2. Rest of Middle East & Africa Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Dose, 2020-2032
12.4.3. Rest of Middle East & Africa Hepatitis B Vaccine Revenue (USD Billion) and Forecast By End-User, 2020-2032
12.5. Middle East & Africa PEST Analysis
CHAPTER 13. Player Analysis Of Hepatitis B Vaccine Market
13.1. Hepatitis B Vaccine Market Company Share Analysis
13.2. Competition Matrix
13.2.1. Competitive Benchmarking of key players by price, presence, market share, and R&D investment
13.2.2. New Product Launches and Product Enhancements
13.2.3. Mergers And Acquisition In Global Hepatitis B Vaccine Market
13.2.4. Partnership, Joint Ventures and Strategic Alliances/ Sales Agreements
CHAPTER 14. Company Profile
14.1. Novartis AG
14.1.1. Company Snapshot
14.1.2. Business Overview
14.1.3. Financial Overview
14.1.3.1. Revenue (USD Billion), 2022
14.1.3.2. Novartis AG 2022 Hepatitis B Vaccine Business Regional Distribution
14.1.4. Product /Service and Specification
14.1.5. Recent Developments & Business Strategy
14.2. CSL Ltd
14.3. Dynavax Technologies
14.4. Beijing Minhai Biotechnology
14.5. Emergent Biosolutions
14.6. GlaxoSmithKline Biologicals
14.7. Merck & Co, Inc
14.8. Pfizer Inc.
14.9. Sanofi Pasteur
14.10. Serum Institute of India
14.11. Emergent Biosolutions
14.12. Sinovac Biotech
Frequently Asked Questions
What was the market size of the global hepatitis B vaccine in 2022?
The market size of hepatitis B vaccine was USD 5.6 billion in 2022.
What is the CAGR of the global hepatitis B vaccine market from 2023 to 2032?
The CAGR of hepatitis B vaccine is 5.5% during the analysis period of 2023 to 2032.
Which are the key players in the hepatitis B vaccine market?
The key players operating in the global market are including Novartis AG, CSL Ltd, Dynavax Technologies, Beijing Minhai Biotechnology, Emergent Biosolutions, GlaxoSmithKline Biologicals, Merck & Co, Inc, Pfizer Inc., Sanofi Pasteur, Serum Institute of India, Emergent Biosolutions, and Sinovac Biotech.
Which region dominated the global hepatitis B vaccine market share?
North America held the dominating position in hepatitis B vaccine industry during the analysis period of 2023 to 2032.
Which region registered fastest CAGR from 2023 to 2032?
Asia-Pacific region exhibited fastest growing CAGR for market of hepatitis B vaccine during the analysis period of 2023 to 2032.
What are the current trends and dynamics in the global hepatitis B vaccine industry?
The current trends and dynamics in the hepatitis B vaccine industry include growing awareness of hepatitis B's health risks, expanding vaccination programs in developing countries, rising healthcare expenditure globally, and technological advancements in vaccine development.
Which type held the maximum share in 2022?
The combination vaccines type held the maximum share of the hepatitis B vaccine industry.
Select Licence Type
Connect with our sales team
Why Acumen Research And Consulting
100%
Customer Satisfaction
24x7
Availability - we are always there when you need us
200+
Fortune 50 Companies trust Acumen Research and Consulting
80%
of our reports are exclusive and first in the industry
100%
more data and analysis
1000+
reports published till date
